
Clinigen chief executive joins Ergomed board
pharmafile | May 28, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Clinigen, ergomed, george
UK drug development services firm Ergomed has appointed Peter George to its board as a non-executive director.
George has over 20 years’ experience in the industry and is currently chief executive of speciality pharma services firm the Clinigen Group.
Prior to Clinigen he was chief executive at Penn Pharma, and previously was executive VP for Wolters Kluwer Health with responsibility for Europe and Asia-Pacific regions.
George has also held roles as the chief operating officer of Unilabs Clinical Trials International Limited; head of Clinical Pathology NHS and as director of PharmaPatents Global.
Chairman of Ergomed Rolf Stahel says: “We are delighted that Peter has joined Ergomed as non-executive director. He has an excellent track record of building international pharmaceutical services businesses.”
George adds: “I am very pleased to join the board of Ergomed. The company has shown strong growth since its inception 15 years ago and I have been very impressed with the expertise and quality within the company. I believe Ergomed has great potential and look forward to being a part of the team.”
Related Content

EUSA Pharma’s COVID-19 drug improves or stabilises respiratory condition in 76% of patients
EUSA Pharma has unveiled promising preliminary findings from an interim analysis of siltuximab in the …

EUSA Pharma and Ergomed partner to investigate IL-6 targeting in COVID-19 patients with serious respiratory complications
Oncology and rare disease firm EUSA Pharma is aiding in the global fight against the …

Clinigen becomes sole license holder of cancer drug Proleukin in $210m deal
Novartis has arranged to sell the remainder of its rights to its skin and lung …






